Pacira BioSciences Inc (PCRX)
30.30
-0.52
(-1.69%)
USD |
NASDAQ |
May 15, 15:01
Pacira BioSciences Cash from Investing (Quarterly): -15.53M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -15.53M |
December 31, 2023 | 8.374M |
September 30, 2023 | -4.342M |
June 30, 2023 | 7.326M |
March 31, 2023 | 66.18M |
December 31, 2022 | 11.19M |
September 30, 2022 | -47.52M |
June 30, 2022 | 19.16M |
March 31, 2022 | -208.02M |
December 31, 2021 | 66.92M |
September 30, 2021 | -35.08M |
June 30, 2021 | 3.033M |
March 31, 2021 | -55.66M |
December 31, 2020 | -82.32M |
September 30, 2020 | -202.85M |
June 30, 2020 | 36.12M |
March 31, 2020 | -28.57M |
December 31, 2019 | -30.80M |
September 30, 2019 | 5.625M |
June 30, 2019 | -181.80M |
March 31, 2019 | 78.48M |
December 31, 2018 | -123.16M |
September 30, 2018 | 94.46M |
June 30, 2018 | 59.57M |
March 31, 2018 | -10.29M |
Date | Value |
---|---|
December 31, 2017 | 8.699M |
September 30, 2017 | -27.48M |
June 30, 2017 | -61.15M |
March 31, 2017 | -143.84M |
December 31, 2016 | -6.917M |
September 30, 2016 | -13.32M |
June 30, 2016 | -19.64M |
March 31, 2016 | -21.88M |
December 31, 2015 | 7.296M |
September 30, 2015 | -8.742M |
June 30, 2015 | -18.01M |
March 31, 2015 | 0.20M |
December 31, 2014 | 2.306M |
September 30, 2014 | -101.18M |
June 30, 2014 | -30.57M |
March 31, 2014 | 9.019M |
December 31, 2013 | 15.22M |
September 30, 2013 | 3.615M |
June 30, 2013 | -5.523M |
March 31, 2013 | -56.25M |
December 31, 2012 | 22.36M |
September 30, 2012 | -1.809M |
June 30, 2012 | -47.54M |
March 31, 2012 | -2.53M |
December 31, 2011 | -11.77M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-208.02M
Minimum
Mar 2022
66.92M
Maximum
Dec 2021
-33.43M
Average
-9.936M
Median
Cash from Investing (Quarterly) Benchmarks
Arbutus Biopharma Corp | 11.69M |
Ligand Pharmaceuticals Inc | -3.775M |
Chimerix Inc | 8.675M |
Karyopharm Therapeutics Inc | 21.94M |
FibroGen Inc | 51.28M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | 49.10M |
Cash from Financing (Quarterly) | -2.817M |
Free Cash Flow | 173.19M |
Free Cash Flow Per Share (Quarterly) | 0.8864 |
Free Cash Flow to Equity (Quarterly) | 48.37M |
Free Cash Flow to Firm (Quarterly) | 46.26M |
Free Cash Flow Yield | 10.15% |